PFIZER INC — Director's Dealing 2025

Feb 26, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2025-02-22

Reporting Person: DAMICO JENNIFER B. (SVP & Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-22	Common Stock	M	8741.0000	$30.1700	Acquired	17602.0000	Direct
2025-02-22	Common Stock	F	390.0000	$26.3000	Disposed	17212.0000	Direct
2025-02-22	Common Stock	F	7798.0000	$26.0800	Disposed	9414.0000	Direct
2025-02-23	Common Stock	F	390.0000	$26.3000	Disposed	9024.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-22	Stock Appreciation Rights	$30.1700	M	8741.0000	Disposed	2025-02-22	Common Stock (8741.0000)	Direct

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: Price is the closing price of Pfizer common stock on February 21, 2025.

F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F6: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).